-
公开(公告)号:US07842693B2
公开(公告)日:2010-11-30
申请号:US10732897
申请日:2003-12-09
申请人: Andrew M. K. Pennell , James B. Aggen , J. J. Kim Wright , Subhabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi , Valeri V. Martichonok
发明人: Andrew M. K. Pennell , James B. Aggen , J. J. Kim Wright , Subhabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi , Valeri V. Martichonok
IPC分类号: A61K31/496 , A61K31/5377 , C07D401/12 , C07D403/12 , C07D413/12 , C07D413/14 , C07D401/14 , C07D409/14
CPC分类号: C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D233/56 , C07D235/06 , C07D249/12 , C07D257/04 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D409/04 , C07D473/34
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂的化合物,并且在用于CCR1的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US07589199B2
公开(公告)日:2009-09-15
申请号:US11008774
申请日:2004-12-08
申请人: Andrew M. K. Pennell , James B. Aggen , J. J. Kim Wright , Subhabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi , Wei Chen , Penglie Zhang
发明人: Andrew M. K. Pennell , James B. Aggen , J. J. Kim Wright , Subhabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi , Wei Chen , Penglie Zhang
IPC分类号: A61K31/496 , C07D401/14 , C07D403/14
CPC分类号: C07D403/04 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/52 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D233/61 , C07D235/06 , C07D235/16 , C07D249/08 , C07D249/14 , C07D257/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/04 , C07D407/04 , C07D409/04 , C07D413/04 , C07D413/12 , C07D417/04 , C07D471/04 , C07D473/34 , A61K2300/00
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US08324216B2
公开(公告)日:2012-12-04
申请号:US12555650
申请日:2009-09-08
申请人: Andrew M. K. Pennell , James B. Aggen , J. J. Kim Wright , Subhabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi , Wei Chen , Penglie Zhang
发明人: Andrew M. K. Pennell , James B. Aggen , J. J. Kim Wright , Subhabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi , Wei Chen , Penglie Zhang
IPC分类号: A61K31/496 , C07D233/61 , C07D249/14 , C07D257/04
CPC分类号: C07D403/04 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/52 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D233/61 , C07D235/06 , C07D235/16 , C07D249/08 , C07D249/14 , C07D257/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/04 , C07D407/04 , C07D409/04 , C07D413/04 , C07D413/12 , C07D417/04 , C07D471/04 , C07D473/34 , A61K2300/00
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US07435830B2
公开(公告)日:2008-10-14
申请号:US11071880
申请日:2005-03-02
申请人: Andrew M. K. Pennell , James B. Aggen , J. J. Kim Wright , Subhabrata Sen , Wei Chen , Daniel Joseph Dairaghi , Penglie Zhang
发明人: Andrew M. K. Pennell , James B. Aggen , J. J. Kim Wright , Subhabrata Sen , Wei Chen , Daniel Joseph Dairaghi , Penglie Zhang
IPC分类号: C07D487/04
CPC分类号: C07D487/04 , C07D471/10 , C07D487/08
摘要: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.
-
公开(公告)号:US07435831B2
公开(公告)日:2008-10-14
申请号:US11219637
申请日:2005-09-01
申请人: Wei Chen , Penglie Zhang , James B. Aggen , Daniel Joseph Dairaghi , Andrew M. K. Pennell , Subhabrata Sen , J. J. Kim Wright
发明人: Wei Chen , Penglie Zhang , James B. Aggen , Daniel Joseph Dairaghi , Andrew M. K. Pennell , Subhabrata Sen , J. J. Kim Wright
IPC分类号: C07D487/04
CPC分类号: C07D471/10 , C07D487/04 , C07D487/08
摘要: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.
摘要翻译: 提供了作为CCR1,CCR2和CCR3受体中一种或多种的有效调节剂的化合物。 化合物通常是具有芳基和杂芳基组分的稠合,螺或氮杂环,并且可用于药物组合物,用于治疗CCR1,CCR2和/或CCR3介导的疾病的方法,以及用于测定中的对照 用于鉴定上述趋化因子受体的竞争性受体拮抗剂。
-
公开(公告)号:US07157464B2
公开(公告)日:2007-01-02
申请号:US10460752
申请日:2003-06-11
申请人: Andrew M. K. Pennell , James B. Aggen , J.J. Kim Wright , Subrabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi
发明人: Andrew M. K. Pennell , James B. Aggen , J.J. Kim Wright , Subrabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi
IPC分类号: C07D403/06 , C07D409/14 , A61K31/496
CPC分类号: C07D473/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D233/56 , C07D235/06 , C07D249/12 , C07D257/04 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D409/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂的化合物,并且在用于CCR1的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US20100240618A1
公开(公告)日:2010-09-23
申请号:US12555650
申请日:2009-09-08
申请人: Andrew M.K. Pennell , James B. Aggen , J.J. Kim Wright , Subhabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi , Wei Chen , Penglie Zhang
发明人: Andrew M.K. Pennell , James B. Aggen , J.J. Kim Wright , Subhabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi , Wei Chen , Penglie Zhang
IPC分类号: A61K31/655 , A61K31/551 , A61K31/5377 , A61K31/496 , A61K31/506 , A61K31/4709 , C07C245/04 , C07D413/14 , C07D473/00 , C07D403/14 , C07D401/14 , C07D403/12 , A61P37/06 , A61P29/00
CPC分类号: C07D403/04 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/52 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D233/61 , C07D235/06 , C07D235/16 , C07D249/08 , C07D249/14 , C07D257/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/04 , C07D407/04 , C07D409/04 , C07D413/04 , C07D413/12 , C07D417/04 , C07D471/04 , C07D473/34 , A61K2300/00
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US07449576B1
公开(公告)日:2008-11-11
申请号:US11491540
申请日:2006-07-21
申请人: Andrew M.K. Pennell , James B. Aggen , J.J. Kim Wright , Subrabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi
发明人: Andrew M.K. Pennell , James B. Aggen , J.J. Kim Wright , Subrabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi
IPC分类号: C07D401/12 , C07D403/12
CPC分类号: C07D473/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D233/56 , C07D235/06 , C07D249/12 , C07D257/04 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D409/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂的化合物,并且在用于CCR1的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US20080261987A1
公开(公告)日:2008-10-23
申请号:US11491540
申请日:2006-07-21
申请人: Andrew M.K. Pennell , James B. Aggen , J.J. Kim Wright , Subrabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi
发明人: Andrew M.K. Pennell , James B. Aggen , J.J. Kim Wright , Subrabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi
IPC分类号: A61K31/53 , A61K31/506 , A61K31/501 , A61K31/496 , A61K31/495 , C07D403/02
CPC分类号: C07D473/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D233/56 , C07D235/06 , C07D249/12 , C07D257/04 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D409/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂的化合物,并且在用于CCR1的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US07871997B2
公开(公告)日:2011-01-18
申请号:US12004251
申请日:2007-12-19
申请人: Paul R. Fatheree , Martin S. Linsell , Daniel Marquess , Daniel D. Long , Jason P. Chinn , Matthew B. Nodwell , Edmund J. Moran , James B. Aggen
发明人: Paul R. Fatheree , Martin S. Linsell , Daniel Marquess , Daniel D. Long , Jason P. Chinn , Matthew B. Nodwell , Edmund J. Moran , James B. Aggen
IPC分类号: A61K31/546 , C07D501/42 , C07D501/44
CPC分类号: C07D519/00 , A61K38/00 , C07D501/46 , C07K9/008
摘要: This invention provides cephalosporin compounds and salts thereof. Such compounds are useful for preparing cross-linked glycopeptide-cephalosporin antibiotics.
摘要翻译: 本发明提供了头孢菌素化合物及其盐。 这样的化合物可用于制备交联的糖肽 - 头孢菌素抗生素。
-
-
-
-
-
-
-
-
-